Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 25
- Registration Number
- NCT04816838
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04816214
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Fondazione Ricerca Traslazionale
- Target Recruit Count
- 170
- Registration Number
- NCT04811001
- Locations
- 🇮🇹
IRCCS Istituto Tumori "Giovanni Paolo II", Bari, BA, Italy
🇮🇹Istituto Toscano Tumori Ospedale San Donato, Arezzo, AR, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2023-12-11
- Target Recruit Count
- 18
- Registration Number
- NCT04780568
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Instituto Oncológico Dr Rosell
- Target Recruit Count
- 32
- Registration Number
- NCT04772235
- Locations
- 🇪🇸
Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain
🇪🇸Hospital Son Espases, Palma, Baleares, Spain
🇪🇸Hospital Universitario Gregorio Marañón, Madrid, Spain
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04770688
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib
- Conditions
- Interventions
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Beijing Cancer Prevention & Treatment Society
- Target Recruit Count
- 150
- Registration Number
- NCT04769388
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 69
- Registration Number
- NCT04762199
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT04743505
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 81
- Registration Number
- NCT04721015
- Locations
- 🇮🇱
Rambam Health Care Campus /ID# 225586, Haifa, H_efa, Israel
🇫🇷AP-HM - Hopital de la Timone /ID# 225779, Marseille CEDEX 05, Bouches-du-Rhone, France
🇺🇸Washington University-School of Medicine /ID# 225698, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.